Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Feb 06, 2023 9:47pm
438 Views
Post# 35270834

%s of the optimized group @450-days: 43.7% CR and 64.4% TR

%s of the optimized group @450-days: 43.7% CR and 64.4% TR
Considering this, in the Jan. 3rd article:
 

In November 2022, Theralase reported encouraging interim clinical data from the pivotal clinical study, with 53% (43 evaluable patients) achieving a complete response at 90 days; 29% (34 evaluable patients) at 360 days; and 28% (29 evaluable patients) at 450 days.

Including patients with an indeterminate response (negative cystoscopy and positive urine cytology, where upper of lower tract UCC has not been identified but is still under investigation by the clinical study sites) patients exhibited a total response are 67% at 90 days; 44% at 360 days; and 38% at 450 days.

1) CR @450-days for the optimized group: 
 
Lets try to assess the CR @450-days in order to have a better understanding of where we could be heading, the more we had new patients.
 
29 evaluable patients = 3 from Ph. 1b + 12 undertreated + 14 optimized (p#13-p#26 as p#26 was in the Nov. 30 stats)
 
28% of 29 patients = 8.12 CR patients @450-days
 
Lets assume 0 CR patients @450-days from the 12 undertreated for a moment, to play this conservative.  
 
That would be 8.12 CR patients @450-days  -  2 CR patients @450-days from Ph. 1b (p#5-6).  So 6.12 CR patients @450-days  patients from the optimized group.
 
6.12 CR patients @450-days  out of 14 from the optimized group = 43.7% CR patients @450-days   
 
 
2) TR @450-days for the optimized group:
 
Lets try to assess the TR @450-days in order to have a better understanding of where we could be heading, the more we had new patients.
 
29 evaluable patients = 3 from Ph. 1b + 12 undertreated + 14 optimized (p#13-p#26 as p#26 was in the Nov. 30 stats)
 
38% of 29 patients = 11.02 TR patients @450-days
 
Lets assume 0 TR patients @450-days from the 12 undertreated for a moment, to play this conservative.  
 
That would be 11.02 TR patients @450-days  -  2 TR patients @450-days from Ph. 1b (p#5-6).  So 9.02 TR patients @450-days  patients from the optimized group.
 
9.02 TR patients @450-days  out of 14 from the optimized group = 64.4% TR patients @450-days

<< Previous
Bullboard Posts
Next >>